WO1991015200A3 - Utilisation trinitrobenzenes ou d'acide carminique pour le traitement du cancer ou de maladies virales - Google Patents

Utilisation trinitrobenzenes ou d'acide carminique pour le traitement du cancer ou de maladies virales Download PDF

Info

Publication number
WO1991015200A3
WO1991015200A3 PCT/GB1991/000517 GB9100517W WO9115200A3 WO 1991015200 A3 WO1991015200 A3 WO 1991015200A3 GB 9100517 W GB9100517 W GB 9100517W WO 9115200 A3 WO9115200 A3 WO 9115200A3
Authority
WO
WIPO (PCT)
Prior art keywords
carminic acid
cancer
compounds
trinitrobenzenes
treatment
Prior art date
Application number
PCT/GB1991/000517
Other languages
English (en)
Other versions
WO1991015200A2 (fr
Inventor
Washington Odur Ayuko
Original Assignee
Washington Odur Ayuko
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB909007453A external-priority patent/GB9007453D0/en
Priority claimed from GB909012166A external-priority patent/GB9012166D0/en
Priority claimed from GB919103075A external-priority patent/GB9103075D0/en
Application filed by Washington Odur Ayuko filed Critical Washington Odur Ayuko
Priority to AU75604/91A priority Critical patent/AU662883B2/en
Priority to MC91GB9100517D priority patent/MC2246A1/fr
Priority to JP3506514A priority patent/JPH06501449A/ja
Priority to BR919106310A priority patent/BR9106310A/pt
Publication of WO1991015200A2 publication Critical patent/WO1991015200A2/fr
Publication of WO1991015200A3 publication Critical patent/WO1991015200A3/fr
Priority to NO92923824A priority patent/NO923824L/no
Priority to LVP-92-149A priority patent/LV10574B/en
Priority to FI924475A priority patent/FI924475A0/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/04—Nitro compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Abstract

Composés de radicaux à base de trinitrobenzène, acide carminique et ses dérivés, utilisables comme agents anti-cancer et anti-virus. Ces composés et les formules basées sur ceux-ci, peuvent s'administrer par voie orale ou parentérale à un malade humain ou animal, en solution/suspension aqueuse pratiquement pure dans une plage de dilutions située entre 10?-3 et 10-15¿ en concentrations molaires. Selon une application préférentielle de l'invention, on utilise un ou davantage desdits composés et un anthraquinone (comme l'acide carminique). L'acide carminique seul présente des effets anti-virus notoires.
PCT/GB1991/000517 1990-04-03 1991-04-03 Utilisation trinitrobenzenes ou d'acide carminique pour le traitement du cancer ou de maladies virales WO1991015200A2 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
AU75604/91A AU662883B2 (en) 1990-04-03 1991-04-03 Use of trinitrobenzenes or carminic acid in the treatment of cancer or viral diseases
MC91GB9100517D MC2246A1 (fr) 1990-04-03 1991-04-03 Utilisation de trinitrobenzenes ou d'acide carminique dans le traitement du cancer ou des maladies virales
JP3506514A JPH06501449A (ja) 1990-04-03 1991-04-03 癌またはウイル性疾患の治療におけるトリニトロベンゼン類またはカルミン酸の使用
BR919106310A BR9106310A (pt) 1990-04-03 1991-04-03 Formulacao para terapia ou profilaxia de neoplasma ou infeccao viral formulacao farmaceutica ou veterinaria,radial ou composto,formulacao para a terapia de infeccao viral e glicosido de anfraquinona
NO92923824A NO923824L (no) 1990-04-03 1992-10-01 Bruk av trinitrobenzener eller karminsyre ved behandling av kreft eller virussykdommer
FI924475A FI924475A0 (fi) 1990-04-03 1992-10-05 Anvaendning av trinitrobensener och karminsyra vid behandling av canceroch virusbetingade sjukdomar
LVP-92-149A LV10574B (en) 1990-04-03 1992-10-05 The therapeutic use of low concentrations of trinitrobenzene, carminic acid and their derivatives as anti-cancer and anti-viral agents

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB909007453A GB9007453D0 (en) 1990-04-03 1990-04-03 Tumour therapy
GB9007453.5 1990-04-03
GB909012166A GB9012166D0 (en) 1990-05-31 1990-05-31 Hydrazine derivatives for cancer therapy
GB9012166.6 1990-05-31
GB919103075A GB9103075D0 (en) 1991-02-13 1991-02-13 Trinitrobenzene derivatives and their therapeutic use
GB9103075.9 1991-02-13

Publications (2)

Publication Number Publication Date
WO1991015200A2 WO1991015200A2 (fr) 1991-10-17
WO1991015200A3 true WO1991015200A3 (fr) 1992-03-05

Family

ID=27265028

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1991/000517 WO1991015200A2 (fr) 1990-04-03 1991-04-03 Utilisation trinitrobenzenes ou d'acide carminique pour le traitement du cancer ou de maladies virales

Country Status (11)

Country Link
EP (1) EP0524212A1 (fr)
JP (1) JPH06501449A (fr)
AU (1) AU662883B2 (fr)
BR (1) BR9106310A (fr)
CA (1) CA2079803A1 (fr)
FI (1) FI924475A0 (fr)
HU (1) HUT62785A (fr)
LV (1) LV10574B (fr)
MC (1) MC2246A1 (fr)
NO (1) NO923824L (fr)
WO (1) WO1991015200A2 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9103075D0 (en) * 1991-02-13 1991-03-27 Washington Odur Ayuko Trinitrobenzene derivatives and their therapeutic use
US5412123A (en) * 1993-02-08 1995-05-02 Glycomed Incorporated Anthraquinone and anthracene derivatives as inhibitors of the cell-adhesion molecules of the immune system
GB2312375B (en) * 1993-05-21 1998-02-25 Radopath Ltd Agents for treatment of cancer
DZ1781A1 (fr) * 1993-05-21 2002-02-17 Radopah Ltd Agents d'arylation.
GB9310520D0 (en) 1993-05-21 1993-07-07 Radopath Ltd Arylating agents
DE69519722D1 (de) * 1994-03-17 2001-02-01 Radopath Pharmaceuticals Inter Wirkstof gegen viren und krebs
WO1996029067A1 (fr) * 1995-03-17 1996-09-26 Radopath Limited Agents antiviraux et anticancereux
GB9615619D0 (en) * 1996-03-18 1996-09-04 Radopath Ltd Costimulation of TcR/CD3-induced T-Lymphocytes
AU1903699A (en) * 1997-12-08 1999-06-28 Glycomed Incorporated Disalicylate analog based sialyl lewisx mimetics
JP2021530605A (ja) * 2018-07-17 2021-11-11 ピリ アントラキノン系誘導体及び着色剤としてのそれらの使用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4032659A (en) * 1969-03-20 1977-06-28 American Home Products Corporation Method of viral chemoprophylaxis
US4724230A (en) * 1982-09-17 1988-02-09 Therapeutical Systems Corp. Method for producing oncolysis
EP0314580A1 (fr) * 1987-10-30 1989-05-03 Institut Pasteur Application de groupes nitrophényles à la stimulation des capacités d'incorporation d'un médicament dans les cellules sensibles de l'hôte

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4032659A (en) * 1969-03-20 1977-06-28 American Home Products Corporation Method of viral chemoprophylaxis
US4724230A (en) * 1982-09-17 1988-02-09 Therapeutical Systems Corp. Method for producing oncolysis
EP0314580A1 (fr) * 1987-10-30 1989-05-03 Institut Pasteur Application de groupes nitrophényles à la stimulation des capacités d'incorporation d'un médicament dans les cellules sensibles de l'hôte

Non-Patent Citations (13)

* Cited by examiner, † Cited by third party
Title
ANTICANCER RESEARCH, vol. 7, no. 4B, July-August 1987, (Athens, GR), T. FUJII et al.: "Effect of PSK on prohibited immunity of splenectomized mice", pages 845-848, see results; discussion *
BIOORGANIC CHEMISTRY, vol. 8, no. 1, March 1979, (London, GB), J.W. LOWN et al.: "Reactions of the antitumor agent carminic acid and derivatives with DNA", pages 17-24, see abstract *
COMPTES RENDUS DES SEANCES DE LA SOCIETE DE BIOLOGIE ET DE SES FILIALES, vol. 167, no. 8, 1973, (Paris, FR), C. DEBY et al.: "Influence d'un régime enrichi en acides gras non saturés sur la toxicité du diphénylpicrylhydrazyl", pages 1302-1305, see abstract *
IMMUNITY TO CANCER. II. PROCEEDINGS OF THE 2ND CONFERENCE ON IMMUNITY TO CANCER, Williamsburg, Virginia, 9-11 November 1987, Alan R. Liss, Inc., (New York, US), A.M. FRIEDMAN et al.: "Prevention of tumor growth and enhancement of cell-mediated immunity by an antigen-specific contrasuppressor factor fram a T cell hybridoma", pages 281-288, see the whole article *
IMMUNOLOGY, vol. 51, no. 4, April 1984, (Oxford, GB), I. ENANDER et al.: "Mononuclear cells, mast cells and mucous cells as part of the delayed hypersensitivity response to aerosolized antigen in mice", pages 661-668, see abstract *
IMMUNOLOGY, vol. 54, no. 2, February 1985, (Oxford, GB), P.M. COMOGLIO et al.: "Enhancement of immunity against RSV-induced sarcomas by generation of hapten-reactive helper T lymphocytes", pages 289-295, see the whole article, esp. page 291, figure 1 *
IMMUNOLOGY, vol. 66, no. 4, April 1989, (Oxford, GB), I. KIMBER et al.: "Regulation of lymphocyte proliferation in contact sensitivity: homeostatic mechanisms and a possible explanation of antigenic competition", pages 577-582, see the whole article *
LIFE SCIENCES, vol. 42, no. 15, 1988, (Oxford, GB), J.M. JAMISON et al.: "Enhancement of the antiviral and interferon-inducing activities of poly r(A-U) by carminic acid", pages 1477-1483, see page 1474, table 1 *
PATENT ABSTRACTS OF JAPAN, vol. 5, no. 102 (C-61)[774], 2 July 1981, & JP,A,5643210 (KOUTAKU HAYASHI) 21 April 1981, see abstract *
REV. CHIR., ONCOL., RADIOL., ORL, OFTALMOL., STOMATOL.: ONCOL., vol. 28, no. 2, 1989, (RO), N. MIHAIL et al.: "Cytostatic action of histological stains for nucleic acids", pages 115-121, see pages 115-116 *
REVUE EUROPEENNE D'ETUDES CLINIQUES ET BIOLOGIQUES, vol. 15, no. 6, 1970, (Paris, FR), C. DEBY et al.: "Effect of a stable free-radical on the survival of x-irradiated mice", pages 678-682, see results *
THE JOURNAL OF EXPERIMENTAL MEDICINE, vol. 156, no. 1, 1st July 1982, (New York, US), W.R. THOMAS et al.: "Hapten-specific T cell lines mediating delayed hypersensitivity to contact-sensitizing agents", pages 300-305, see results; discussion *
ZHURNAL OBSCHEI KHIMII, vol. 32, no. 12, December 1962, (SU), M.A. IKRINA et al.: "Investigations in the field of the chemistry of free radicals of the hydrazine series VIII" (applicant's translation), pages 3952-3957, see the whole article (cited in the application) *

Also Published As

Publication number Publication date
NO923824D0 (no) 1992-10-01
NO923824L (no) 1992-11-26
MC2246A1 (fr) 1993-03-25
HU9203148D0 (en) 1992-12-28
LV10574A (lv) 1995-04-20
LV10574B (en) 1995-08-20
FI924475A (fi) 1992-10-05
AU662883B2 (en) 1995-09-21
FI924475A0 (fi) 1992-10-05
BR9106310A (pt) 1993-04-20
EP0524212A1 (fr) 1993-01-27
JPH06501449A (ja) 1994-02-17
WO1991015200A2 (fr) 1991-10-17
CA2079803A1 (fr) 1991-10-04
AU7560491A (en) 1991-10-30
HUT62785A (en) 1993-06-28

Similar Documents

Publication Publication Date Title
ZA928170B (en) Antiviral 4-substituted-2-deoxy-2,3-didehydro-derivatives of alpha-D-neuraminic acid
ATE76748T1 (de) Arzneimittel fuer den bereich der mundhoehle.
MD1224B2 (en) Application of nucleoside analogues with 1,3-oxathiolan for treatment of hepatitis B
RU93047799A (ru) Композиции, содержащие ретиноевые кислоты и токоферол
ATE131730T1 (de) Nukleosidanalogen enthaltende antiviren- zubereitungen
FI832355A0 (fi) 9-(2-hydroxyetoximetyl)guanidin-derivat
DE3766200D1 (de) L-dopa enthaltendes arzneimittel.
ATE79538T1 (de) Dispergierbare zubereitung.
WO1991015200A3 (fr) Utilisation trinitrobenzenes ou d&#39;acide carminique pour le traitement du cancer ou de maladies virales
ATE99172T1 (de) Verwendung von acetyl-l-carnitin zur behandlung von katarakt, sowie pharmazeutische zusammensetzungen fuer eine derartige behandlung.
CA2042972A1 (fr) Traitement de l&#39;hypertension oculaire au moyen d&#39;une combinaison synergique pour administration oculaire
CA2060560A1 (fr) Methode pour assurer un apport suffisant en glutathione intracellulaire dans les tissus
MC1930A1 (fr) Produit antiviral
DE68900187D1 (de) Pentamidin enthaltende arzneimittel.
DE69019404D1 (de) Derivate von Penciclovir zur Behandlung von Hepatitis-B-Infektionen.
KR910005886A (ko) 안정화 백혈구 인터페론
PH27567A (en) Topical compositions
KR880004810A (ko) 소화성 궤양 치료제
HK1012242A1 (en) Topical composition containing penciclovir
JPS6438030A (en) Preventing and treating agent for aids
ATE104676T1 (de) Antivirale wirkstoffe.
GB2208798B (en) Anti-cancer agent comprising l-ascorbic acid and o-benzylidene-l-ascorbic acid or deuterated derivative
GR3017335T3 (en) Oligophosphates with antiviral activity.
CA2193665A1 (fr) Derives de benzimidazole pour le traitement et la prophylaxie d&#39;infections virales
MD940165A (ro) Remediu pentru tratarea cancerului sau a afecţiunilor virotice

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU BB BG BR CA FI HU JP KP KR LK MC MG MW NO PL RO SD SU US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE BF BJ CF CG CH CM DE DK ES FR GA GB GR IT LU ML MR NL SE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AU BB BG BR CA FI HU JP KP KR LK MC MG MW NO PL RO SD SU US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE BF BJ CF CG CH CM DE DK ES FR GA GB GR IT LU ML MR NL SE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2079803

Country of ref document: CA

Ref document number: 1991907059

Country of ref document: EP

Ref document number: 92-01277

Country of ref document: RO

WWE Wipo information: entry into national phase

Ref document number: 924475

Country of ref document: FI

WWP Wipo information: published in national office

Ref document number: 1991907059

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1991907059

Country of ref document: EP